Vivos Inc RDGL
We take great care to ensure that the data presented and summarized in this overview for VIVOS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RDGL
Top Purchases
Top Sells
About RDGL
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
Insider Transactions at RDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.48%
|
$0
$0.14 P/Share
|
|
Sep 30
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.48%
|
$0
$0.16 P/Share
|
|
Aug 13
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.48%
|
$0
$0.11 P/Share
|
|
Aug 07
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.48%
|
$0
$0.12 P/Share
|
|
Aug 01
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.49%
|
$0
$0.09 P/Share
|
|
Jul 29
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.49%
|
$0
$0.09 P/Share
|
|
Jun 04
2024
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
50,000
+0.49%
|
$0
$0.17 P/Share
|
|
Nov 13
2023
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
100,000
+0.98%
|
$0
$0.05 P/Share
|
|
Oct 18
2023
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
100,000
+0.99%
|
$0
$0.05 P/Share
|
|
Mar 24
2023
|
Michael H Pollack INTERIM CFO |
SELL
Open market or private sale
|
Direct |
16,000
-100.0%
|
$0
$0.06 P/Share
|
|
Dec 15
2022
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
100,000
+1.0%
|
$0
$0.05 P/Share
|
|
Nov 17
2022
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
200,000
+2.0%
|
$0
$0.05 P/Share
|
|
Aug 10
2022
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
200,000
+2.04%
|
$0
$0.07 P/Share
|
|
Mar 28
2022
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
100,000
+1.03%
|
$0
$0.06 P/Share
|
|
Mar 27
2022
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
76,250
+0.8%
|
-
|
|
Mar 16
2022
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
22,266
+0.24%
|
-
|
|
Dec 08
2021
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
130,000
+1.24%
|
$0
$0.08 P/Share
|
|
Sep 23
2021
|
Michael K Korenko CEO AND PRESIDENT |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,696
-0.57%
|
$0
$0.12 P/Share
|
|
Sep 23
2021
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+1.44%
|
$0
$0.04 P/Share
|
|
Aug 10
2021
|
Michael K Korenko CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
89,689
+0.88%
|
$0
$0.11 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 350K shares |
|---|